Table 3.

Half maximal inhibitory concentration of monobodies and mAb AM-128 against SARS-CoV-2 wild type and variants of concern.

C4C4-AM2C6bmAb AM-128
WT (B.1.1)IC50 (nM)6.60.0461.60.11
IC50 (ng/ml)880.622217
Alpha (B.1.1.7)IC50 (nM)0.170.0771.60.15
IC50 (ng/ml)2.21.02223
Beta (B.1.351)IC50 (nM)N.D.0.541.90.40
IC50 (ng/ml)N.D.7.22560
Gamma (P.1)IC50 (nM)N.D.0.552.61.9
IC50 (ng/ml)N.D.7.434285
Delta (B.1.617.2)IC50 (nM)N.D.0.598.41.5
IC50 (ng/ml)N.D.8.0114225
  • N.D., not determined.